PT - JOURNAL ARTICLE AU - Agarwal, Vineet AU - Venkatakrishnan, AJ AU - Puranik, Arjun AU - Kirkup, Christian AU - Lopez-Marquez, Agustin AU - Challener, Douglas W. AU - O’Horo, John C. AU - Binnicker, Matthew J. AU - Kremers, Walter K. AU - Faubion, William A. AU - Badley, Andrew D. AU - Williams, Amy W. AU - Gores, Gregory J. AU - Halamka, John D. AU - Morice, William G. AU - Soundararajan, Venky TI - Long-term SARS-CoV-2 RNA Shedding and its Temporal Association to IgG Seropositivity AID - 10.1101/2020.06.02.20120774 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.02.20120774 4099 - http://medrxiv.org/content/early/2020/07/07/2020.06.02.20120774.short 4100 - http://medrxiv.org/content/early/2020/07/07/2020.06.02.20120774.full AB - Analysis of 851 COVID-19 patients with a SARS-CoV-2-positive PCR at follow-up shows 99 patients remained SARS-CoV-2-positive after four weeks from initial diagnosis. Surprisingly, a majority of these long-term viral RNA shedders were not hospitalized (61 of 99), with variable PCR Crossing point values over the month post diagnosis. For the 851-patient cohort, the mean lower bound of viral RNA shedding was 17.3 days (SD: 7.8), and the mean upper bound of viral RNA shedding from 668 patients transitioning to confirmed PCR-negative status was 22.7 days (SD: 11.8). Among 104 patients with an IgG test result, 90 patients were seropositive to date, with mean upper bound of time to seropositivity from initial diagnosis being 37.8 days (95%CI: 34.3-41.3). Juxtaposing IgG/PCR tests revealed that 14 of 90 patients are non-hospitalized and seropositive yet shed viral RNA. This study emphasizes the need for monitoring viral loads and neutralizing antibody titers in long-term shedders.Competing Interest StatementOne or more of the investigators associated with this project and Mayo Clinic have a Financial Conflict of Interest in technology used in the research and that the investigator(s) and Mayo Clinic may stand to gain financially from the successful outcome of the research. The title of the project is IRB 20-003334: 'CDAP Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions'. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies. ADB is a consultant for Abbvie, is on scientific advisory boards for Nference and Zentalis, and is founder and President of Splissen therapeutics. Authors affiliated with nference have financial interests in nference.Funding StatementADB is supported by Grants AI 110173 and AI120698 from NIAID, 109593-62-RGRL from Amfar, and the HH Sheikh Khalifa Bin Zayed Al-Nahyan named professorship from Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mayo Clinic IRB and compliance body approved this research under the IRB20-003334: CDAP Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact the corresponding author regarding data availability. Please review HIPAA regulations and Mayo Clinic IRB guidelines before making any requests.